The J&J-Auris tie-up will yield a huge return for investors who went in big.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.